Innovation
Inven2 are responsible for assessing and commercialising innovative research conducted at the University of Oslo, Oslo University Hospital and the health trusts under the South-Eastern Norway Regional Health Authority.
Since the establishment of Inven2 ten years ago, we have contributed to the establishment of 55 companies and 388 licenses alongside innovative researchers. This has led to NOK 500 million being channelled back to research and innovation.
Innovation motivated by patients
Jan Terje Andersen learnt about laboratory work when he was studying to become a biomedical laboratory scientist. Scientific curiosity led him to the Department of Biosciences at the University of Oslo.
A lecture by Professor Inger Sandlie decided his future career. Today, he is one of the researchers with the most innovations at Inven2.
Information
Portfolio businesses
More businesses
Portfolio businesses
Inven2 has a portfolio comprising 50 companies. We have established them either on our own or alongside investors to commercialise research results from innovative researchers. The point of departure for the companies are research results from innovative researchers. The portfolio value in December 2022 is NOK 11 billion, but this will vary with the value of the individual company and how long we are shareholders in the most valuable companies.
Products on the market
More products
Products on the market
Inven2 has contributed to many products and services that have served society well through licensing to industry or business start-ups within a range of technology fields. What follows is a selection of them.
MULTI-NEEDLE LANGMUIR PROBE (M-NLP)
Photo: Norsk Romsenter
EPISHUTTLE – Transport isolator
Photo: EpiGuard
QUEST 5 HMC DNA ELISA KIT Epigenetic kit
Photo: Zymo Research
Latest innovation news
More news
Latest innovation news
These are news about Inven2’s new and ongoing innovation projects, companies we have been a contributed part in establishing, new products and services on the market and other relevant news regarding innovation.
Licensing validates Norwegian platform technology for the development of tailored monoclonal antibodies
This summer, the U.S.-based biotechnology company Mage Biologics Inc (“Mage Bio”) was formed as a collaboration between the Swiss specialty pharma...
Authera lands collaborative agreement with argenx
The platform company Authera, spun out of research at the University of Oslo and Oslo University Hospital, reports that they have entered into a...
Technology from the University of Oslo is on its way to the moon.
In 2012, we licensed out technology from the University of Oslo to the Norwegian space technology company Eidel. Now this technology is on its way...
